ATYR Q3 2018 Earnings — aTyr Pharma, Inc. Revenue & Financial Results | Market Cap Arena

ATYRaTyr Pharma, Inc.

$89M

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$7M

Net Income

-$7M

EPS (Diluted)

$-3.33

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$690,000

Balance Sheet

Total Assets

$60M

Total Liabilities

$21M

Stockholders' Equity

$39M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$7M	-$11M	+38.3%
Net Income	-$7M	-$11M	+36.4%